WORCESTER, Mass., Jan. 6, 2010 (GLOBE NEWSWIRE) -- With over 40 years experience in the rollercoaster ride of drug development and commercialization, I have been fortunate to have been one of the founders and leaders of a number of multi-billion dollar ventures, including the development of amoxicillin, as well as the founding of Amgen Inc. and SuperGen, Inc. And now, as I have taken on the role of Chief Scientific Advisor for Generex Biotechnology Corporation (Nasdaq:GNBT) (www.generex.com) and am preparing a white paper on the significant proprietary scientific technologies amassed by this still relatively unknown biotechnology company, I feel it is important to reflect on the pivotal year of 2009 which has set the stage for what I believe is an important future in numerous areas.
